clinical trial · NCT05679570
Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
International University of Health and Welfare·phase2·active not recruiting·n = 20
Pulmonary Arterial HypertensionSatralizumab (Genetical Recombination)
brief summary
Examine the efficacy of satralizumab in patients with pulmonary arterial hypertension (PAH) with immune-responsive phenotype serum interleukin-6 (IL-6) ≥ 2.73 pg/mL who have an inadequate response to existing drugs.
started
Jul 12, 2022
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Sep 3, 2025
official title
Satralizumab,an Anti-IL-6 Receptor Antibody, in the Treatment of Pulmonary Arterial Hypertension; Safety and Efficacy Evaluation in Japan -Multicenter, Investigator-sponsored Trial-
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol